Bortezomib partially improves laminin α2 chain-deficient muscular dystrophy

American Journal of Pathology

Volumn 184, Issue 5, 2014, Pages 1518-1528

  Körner, Zandra ^a   Fontes Oliveira, Cibely C ^a   Holmberg, Johan ^a   Carmignac, Virginie ^b   Durbeej, Madeleine ^a  

^a LUND UNIVERSITY   (Sweden)

^b UNIVERSITÉ DE BOURGOGNE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; LAMININ ALPHA2; MICRORNA; MICRORNA 1; MICRORNA 133A; PROTEASOME; UNCLASSIFIED DRUG; BORONIC ACID DERIVATIVE; LAMININ; PYRAZINE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; AUTOPHAGY; BODY WEIGHT; CONTROLLED STUDY; DIAPHRAGM MUSCLE; DRUG EFFECT; DRUG EFFICACY; FETUS; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; LOCOMOTION; MORPHOMETRICS; MOTOR ACTIVITY; MOTOR PERFORMANCE; MOUSE; MUSCLE MASS; MUSCULAR DYSTROPHY; MYOBLAST; MYOFIBROSIS; MYOTUBE; NONHUMAN; NUCLEOTIDE SEQUENCE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUADRICEPS FEMORIS MUSCLE; QUANTITATIVE ANALYSIS; SKELETAL MUSCLE; SURVIVAL; ANIMAL; ANTIBODY SPECIFICITY; C57BL MOUSE; CELL CULTURE; DEFICIENCY; DISEASE MODEL; DRUG EFFECTS; FIBROSIS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MUSCLE; MUSCLE CELL; MUSCULAR DYSTROPHY, ANIMAL; PATHOLOGY;

ANIMALS; APOPTOSIS; BODY WEIGHT; BORONIC ACIDS; BORTEZOMIB; CELLS, CULTURED; DISEASE MODELS, ANIMAL; FIBROSIS; GENE EXPRESSION REGULATION; LAMININ; LOCOMOTION; MICE, INBRED C57BL; MICRORNAS; MUSCLE CELLS; MUSCLES; MUSCULAR DYSTROPHY, ANIMAL; ORGAN SPECIFICITY; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES; SURVIVAL ANALYSIS;

EID: 84899502670     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.1016/j.ajpath.2014.01.019     Document Type: Article

References (66)

1. V. Allamand, and P. Guicheney Merosin-deficient muscular dystrophy, autosomal recessive (MDC1A, MIM#156225, LAMA2 gene coding for α2 chain of laminin) Eur J Hum Genet 10 2002 91 94
2. T. Voit, and F.M.S. Tomé The congenital muscular dystrophies ed 3 A.G. Angel, C. Franzini-Armstrong, Myology: Basic and Clinical vol 2 2004 McGraw-Hill New York 1203 1238
3. I. Leivo, and E. Engvall Merosin, a protein specific for basement membranes of Schwann cells, striated muscle, and trophoblast, is expressed late in nerve and muscle development Proc Natl Acad Sci USA 85 1988 1544 1588
4. H. Xu, P. Christmas, X.R. Wu, U.M. Wewer, and E. Engvall Defective muscle basement membrane and lack of M-laminin in the dystrophic dy/dy mouse Proc Natl Acad Sci USA 91 1994 5572 5576
5. A. Helbling-Leclerc, X. Zhang, H. Topaloglu, C. Cruaud, F. Tesson, J. Weissenbach, F.M.S. Tomé, K. Schwartz, M. Fardeau, K. Tryggvason, and P. Guicheney Mutations in the laminin α2 chain gene (LAMA2) cause merosin-deficient muscular dystrophy Nat Genet 11 1995 216 218
6. O. Ibraghimov-Beskrovnaya, J.M. Ervasti, C.J. Leveille, C.A. Slaughter, S.W. Sernett, and K.P. Campbell Primary structure of dystrophin-associated glycoproteins linking dystrophin to the extracellular matrix Nature 355 1992 696 702
7. J.F. Talts, Z. Andac, W. Gohring, A. Brancaccio, and R. Timpl Binding of the G domains of laminin α1 and α2 chains and perlecan to heparin, sulfatides, α-dystroglycan and several extracellular matrix proteins EMBO J 18 1999 863 870
8. H. von der Mark, I. Williams, O. Wendler, L. Sorokin, K. von der Mark, and E. Pöschl Alternative splice variants of α7β1 integrin selectively recognize different laminin isoforms J Biol Chem 277 2002 6012 6016
9. J.M. Ervasti, and K.P. Campbell A role for the dystrophin-glycoprotein complex as a transmembrane linker between laminin and actin J Cell Biol 122 1993 809 823
10. B.J. Petrof, J.B. Shrager, H.H. Stedman, A.M. Kelly, and H.L. Sweeney Dystrophin protects the sarcolemma from stresses developed during muscle contraction Proc Natl Acad Sci USA 90 1993 3710 3714
11. P.H. Vachon, H. Xu, L. Liu, F. Loechel, Y. Hayashi, K. Arahata, J.C. Reed, U.M. Wewer, and E. Engvall Integrins (α7β1) in muscle function and survival. Disrupted expression in merosin-deficient congenital muscular dystrophy J Clin Invest 10 1997 1870 1881
12. J. Moll, P. Barzaghi, S. Lin, G. Bezakova, H. Lochmüller, E. Engvall, U. Müller, and M.A. Rüegg An agrin minigene rescues dystrophic symptoms in a mouse model for congenital muscular dystrophy Nature 413 2001 302 307
13. K.I. Gawlik, U. Mayer, K. Blomberg, A. Sonnenberg, P. Ekblom, and M. Durbeej Laminin α1 chain mediated reduction of laminin α2 chain deficient muscular dystrophy involves integrin α7β1 and dystroglycan FEBS Lett 580 2006 1759 1765
14. W. Kuang, H. Xu, J.T. Vilquin, and E. Engvall Activation of the Lama2 gene in muscle regeneration: abortive regeneration in laminin α2-deficiency Lab Invest 79 1999 1601 1613
15. Y.K. Hayashi, Z. Tezak, T. Momoi, I. Nonaka, C.A. Garcia, E.P. Hoffman, and K. Arahata Massive muscle cell degeneration in the early stage of merosin-deficient congenital muscular dystrophy Neuromuscul Disord 11 2001 350 359
16. K.I. Gawlik, and M. Durbeej Skeletal muscle laminin and MDC1A: pathogenesis and treatment strategies Skelet Muscle 1 2011 9
17. Y. Miyagoe, K. Hanaoka, I. Nonaka, M. Hayasaka, Y. Nabeshima, K. Arahata, Y. Nabeshima, and S. Takeda Laminin α2 chain-null mutant mice by targeted disruption of the Lama2 gene: a new model of merosin (laminin 2)-deficient congenital muscular dystrophy FEBS Lett 415 1997 33 39
18. L.T. Guo, X.U. Zhang, W. Kuang, H. Xu, L.A. Liu, J.T. Vilquin, Y. Miyagoe-Suzuki, S. Takeda, M.A. Rüegg, U.M. Wewer, and E. Engvall Laminin α2 deficiency and muscular dystrophy; genotype-phenotype correlation in mutant mice Neuromuscul Disord 3 2003 207 215
19. K. Gawlik, Y. Miyagoe-Suzuki, P. Ekblom, S. Takeda, and M. Durbeej Laminin α1 chain reduces muscular dystrophy in laminin α2 chain deficient mice Hum Mol Genet 13 2004 1775 1784
20. K.I. Gawlik, J.Y. Li, Å. Petersén, and M. Durbeej Laminin α1 chain improves laminin α2 chain deficient neuropathy Hum Mol Genet 15 2006 2690 2700
21. K.I. Gawlik, M. Åkerlund, V. Carmignac, H. Elamaa, and M. Durbeej Distinct roles for laminin globular domains in laminin α1 chain mediated rescue of murine laminin α2 chain deficiency PLoS One 5 2010 e11549
22. K.I. Gawlik, and M. Durbeej Transgenic overexpression of laminin α1 chain in laminin α2 chain-deficient mice rescues the disease throughout the lifespan Muscle Nerve 42 2010 30 37
23. W. Kuang, H. Xu, P.H. Vachon, and E. Engvall Merosin-deficient congenital muscular dystrophy. Partial genetic correction in two mouse models [Erratum appeared in J Clin Invest 1998, 102(6):following 1275] J Clin Invest 102 1998 844 852
24. C.F. Bentzinger, P. Barzaghi, S. Lin, and M.A. Rüegg Overexpression of mini-agrin in skeletal muscle increases muscle integrity and regenerative capacity in laminin-α2-deficient mice FASEB J 19 2005 934 942
25. S. Meinen, P. Barzaghi, S. Lin, H. Lochmüller, and M.A. Rüegg Linker molecules between laminins and dystroglycan ameliorate laminin-α2-deficient muscular dystrophy at all disease stages J Cell Biol 176 2007 979 993
26. J.A. Doe, R.D. Wuebbles, E.T. Allred, J.E. Rooney, M. Elorza, and D.J. Burkin Transgenic overexpression of the α7 integrin reduces muscle pathology and improves viability in the dy(W) mouse model of merosin-deficient congenital muscular dystrophy type 1A J Cell Sci 124 2011 2287 2297
27. M. Girgenrath, J.A. Dominov, C.A. Kostek, and J.B. Miller Inhibition of apoptosis improves outcome in a model of congenital muscular dystrophy J Clin Invest 114 2004 1635 1639
28. A. Kumar, J. Yamauchi, T. Girgenrath, and M. Girgenrath Muscle-specific expression of insulin-like growth factor 1 improves outcome in Lama2Dy-w mice, a model for congenital muscular dystrophy type 1A Hum Mol Genet 20 2011 2333 2343
29. M. Erb, S. Meinen, P. Barzaghi, L.T. Sumanovski, I. Courdier-Früh, M.A. Rüegg, and T. Meier Omigapil ameliorates the pathology of muscle dystrophy caused by laminin-α2 deficiency J Pharmacol Exp Ther 331 2009 787 795
30. M. Girgenrath, M.L. Beermann, V.K. Vishnudas, S. Homma, and J.B. Miller Pathology is alleviated by doxycycline in a laminin-α2-null model of congenital muscular dystrophy Ann Neurol 65 2009 47 56
31. 2J mouse Ann Neurol 71 2012 699 708
32. S. Meinen, S. Lin, and M.A. Rüegg Angiotensin II type 1 receptor antagonists alleviate muscle pathology in the mouse model for laminin-α2-deficient congenital muscular dystrophy (MDC1A) Skelet Muscle 2 2012 18
33. J.E. Rooney, J.R. Knapp, B.L. Hodges, R.D. Wuebbles, and D.J. Burkin Laminin-111 protein therapy reduces muscle pathology and improves viability of a mouse model of merosin-deficient congenital muscular dystrophy Am J Pathol 180 2012 1593 1602
34. V. Carmignac, R. Quéré, and M. Durbeej Proteasome inhibition improves the muscle of laminin α2 chain-deficient mice Hum Mol Genet 20 2011 541 552
35. V. Carmignac, M. Svensson, Z. Körner, L. Elowsson, C. Matsumura, K. Gawlik, V. Allamand, and M. Durbeej Autophagy is increased in laminin α2 chain-deficient muscle and inhibition improves muscle morphology in a mouse model of MDC1A Hum Mol Genet 20 2011 4891 4902
36. A.L. Goldberg Development of proteasome inhibitors as research tools and cancer drugs J Cell Biol 199 2012 583 588
37. D. Buac, M. Shen, S. Schmitt, F.R. Kona, R. Deshmukh, Z. Zhang, C. Neslund-Dudas, B. Mitra, and Q.P. Dou From bortezomib to other inhibitors of the proteasome and beyond Curr Pharm Des 19 2013 4025 4038
38. M. Durbeej, R.D. Cohn, R.F. Hrstka, S.A. Moore, V. Allamand, B.L. Davidson, R.A. Williamson, and K.P. Campbell Disruption of the β-sarcoglycan gene reveals pathogenetic complexity of limb-girdle muscular dystrophy type 2E Mol Cell 5 2000 141 151
39. V. Allamand, L. Bidou, M. Arakawa, C. Floquet, M. Shiozuka, M. Paturneau-Jouas, C. Gartioux, G.S. Butler-Browne, V. Mouly, J.P. Rousset, R. Matsuda, D. Ikeda, and P. Guicheney Drug-induced readthrough of premature stop codons leads to the stabilization of laminin α2 chain mRNA in CMD myotubes J Gene Med 10 2008 217 224
40. C. Mammucari, G. Milan, V. Romanello, E. Masiero, R. Rudolf, P. Del Piccolo, S.J. Burden, R. Di Lisi, C. Sandri, J. Zhao, A. Goldberg, S. Schiaffino, and M. Sandri FoxO3 controls autophagy in skeletal muscle in vivo Cell Metab 6 2007 458 471
41. L. Laure, N. Danièle, L. Suel, S. Marchand, S. Aubert, N. Bourg, C. Roudauc, S. Dugez, M. Bartoli, and I. Richard A new pathway encompassing calpain 3 and its newly identified substrate cardiac ankyrin repeat protein is involved in the regulation of the nuclear factor κB pathway in skeletal muscle FEBS J 277 2010 4322 4337
42. C.C. Fontes-Oliveira, S. Busquets, M. Toledo, F. Penna, M. Paz Aylwin, S. Sirisi, A.P. Silva, M. Orpí, A. García, A. Sette, M. Inês Genovese, M. Olivan, F. López-Soriano, and J.M. Argilés Mitochondrial and sarcoplasmic reticulum abnormalities in cancer cachexia: altered energetic efficiency? Biochim Biophys Acta 1830 2013 2770 2778
43. J. Vandesompele, K. De Preter, F. Pattyn, B. Poppe, N. Van Roy, A. De Paepe, and F. Speleman Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes Genome Biol 3 2002 RESEARCH0034
44. M.W. Pfaffl, G.W. Horgan, and L. Dempfle Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR Nucleic Acids Res 30 2002 e36
45. H. Xu, X.R. Wu, U.M. Wewer, and E. Engvall Murine muscular dystrophy caused by a mutation in the laminin α2 (Lama2) gene Nat Genet 8 1994 297 302
46. Y. Sunada, S.M. Bernier, A. Utani, Y. Yamada, and K.P. Campbell Identification of a novel mutant transcript of laminin α2 chain gene responsible for muscular dystrophy and dysmyelination in dy2J mice Hum Mol Genet 4 1995 1055 1061
47. J.V. Welser, J.E. Rooney, N.C. Cohen, P.B. Gurpur, C.A. Singer, R.A. Evans, B.A. Haines, and D.J. Burkin Myotendinous junction defects and reduced force transmission in mice that lack α7 integrin and utrophin Am J Pathol 175 2009 1545 1554
48. E. Gazzerro, S. Assereteo, A. Bonetto, F. Sotiga, S. Scarfi, A. Pistorio, G. Bonuccelli, M. Cilli, C. Bruno, F. Zara, M.P. Lisanti, and C. Minetti Therapeutic potential of proteasome inhibition in Duchenne and Becker muscular dystrophies Am J Pathol 176 2010 1863 1877
49. M. Taniguchi, H. Kurahashi, S. Noguchi, J. Sese, T. Okinaga, T. Tsukahara, P. Guicheney, K. Ozono, I. Nishino, S. Morishita, and T. Toda Expression profiling of muscles from Fukuyama-type congenital muscular dystrophy and laminin α2 deficient congenital muscular dystrophy; is congenital muscular dystrophy a primary fibrotic disease? Biochem Biophys Res Commun 342 2006 489 502
50. I.T. Zaharieva, M. Calissano, M. Scoto, M. Preston, S. Cirak, L. Feng, J. Collins, R. Kole, M. Guglieri, V. Straub, K. Bushby, A. Ferlini, J.E. Morgan, and F.P. Muntoni Dystromirs as serum biomarkers for monitoring the disease severity in Duchenne muscular dystrophy PLoS One 8 2013 e80263
51. T.C. Roberts, K.E. Blomberg, G. McClorey, S. El Andaloussi, C. Godfrey, C. Betts, T. Coursindel, M.J. Gait, C.I. Smith, and M.J. Wood Expression analysis in multiple muscle groups and serum reveals complexity in the microRNA transcriptome of the mdx mouse with implications for therapy Mol Ther Nucleic Acids 1 2012 e39
52. L. Combaret, A.J.A. Olasunkanmi, N. Bedard, V. Baracos, D. Attaix, and S.S. Wing USP19 is a ubiquitin-specific protease regulated in rat skeletal muscle during catabolic states Am J Physiol Endocrinol Metab 288 2005 E693 E700
53. S. Meinen, S. Lin, R. Thurnherr, M. Erb, T. Meier, and M.A. Rüegg Apoptosis inhibitors and mini-agrin have additive benefits in congenital muscular dystrophy mice EMBO Mol Med 3 2011 465 479
54. J.B. Almond, and G.M. Cohen The proteasome: a novel target for cancer chemotherapy Leukemia 16 2002 433 443
55. J. Menashe Managing and avoiding bortezomib toxicity Community Oncol 4 2007 480 484
56. K.M. Kortuem, and A.K. Stewart Carfilzomib Blood 121 2013 893 897
57. K.P. Araujo, G. Bonuccelli, C.N. Duarte, T.P. Gaiad, D.F. Moreira, D. Feder, J.E. Belizario, M.A. Miglino, M.P. Lisanti, and C.E. Ambrosio Bortezomib (PS-341) treatment decreases inflammation and partially rescues the expression of the dystrophin-glycoprotein complex in GRMD dogs PLoS One 8 2013 e61367
58. K.I. Gawlik, J. Holmberg, and M. Durbeej Loss of dystrophin and β-sarcoglycan significantly exacerbates the phenotype of laminin α2 chain-deficient animals Am J Pathol 184 2014 740 752
59. S. Acharyya, S.A. Villalta, N. Bakkar, T. Bupha-Intr, P.M. Janssen, M. Carathers, Z.W. Li, A.A. Beg, S. Ghosh, Z. Sahenk, M. Weinstein, K.L. Gardner, J.A. Rafael-Fortney, M. Karin, J.G. Tidball, A.S. Baldwin, and D.C. Guttridge Interplay of IKK/NF-κB signaling in macrophages and myofibers promotes muscle degeneration in Duchenne muscular dystrophy J Clin Invest 117 2007 889 901
60. G. Bonuccelli, F. Sotgia, W. Schubert, D.S. Park, P.G. Frank, S.E. Woodman, L. Insabato, M. Cammer, C. Minetti, and M.P. Lisanti Proteasome inhibitor (MG-132) treatment of mdx mice rescues the expression and membrane localization of dystrophin and dystrophin-associated proteins Am J Pathol 163 2003 1663 1675
61. S. Assereto, S. Stringara, F. Sotgia, G. Bonuccelli, A. Broccolini, M. Pedemonte, M. Traverso, R. Biancheri, F. Zara, C. Bruno, M.P. Lisanti, and C. Minetti Pharmacological rescue of the dystrophin-glycoprotein complex in Duchenne and Becker skeletal muscle explants by proteasome inhibitor treatment Am J Physiol Cell Physiol 290 2006 C577 C582
62. G. Bonuccelli, F. Sotgia, F. Capozza, E. Gazzerro, C. Minetti, and M.P. Lisanti Localized treatment with a novel FDA-approved proteasome inhibitor blocks the degradation of dystrophin and dystrophin-associated proteins in mdx mice Cell Cycle 6 2007 1242 1248
63. J. Selzby, C. Morris, L. Morris, and L. Sweeney A proteasome inhibitor fails to attenuate dystrophic pathology in mdx mice PLoS Curr 4 2012 e4f84a944d8930
64. B.A. Azakir, S. Di Fulvio, J. Kinter, and M. Sinnreich Proteasomal inhibition restores biological function of mis-sense mutated dysferlin in patient-derived muscle cells J Biol Chem 287 2012 10344 10354
65. C. Mammucari, S. Schiaffino, and M. Sandri Downstream of Akt: FoxO3 and mTOR in the regulation of autophagy in skeletal muscle Autophagy 4 2008 524 526
66. K.J. Langenbach, and T.A. Rando Inhibition of dystroglycan binding to laminin disrupts the PI3K/AKT pathway and survival signaling in muscle Muscle Nerve 26 2002 644 653